Clinical trials: Precancerous/Nonmalignant Condition
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
- Trial name
- NCT04850846
- Testing
- Metformin XR
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Actinic Keratosis
Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
In topical photodynamic therapy (PDT) for non-melanoma skin cancers, a photosensitizing prodrug, 5-aminolaevulinic acid (ALA) or its methylated ester, methyl aminolevulinate (MAL), is converted to the endogenous photosensitizer…
- Trial name
- PDT (NCT02878382)
- Testing
- Conventional MAL-PDT, Calcipotriol assisted MAL-PDT
- Where
- 2 sites in Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Actinic Keratosis
Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
This is a Phase 2 clinical study in patients with actinic keratosis involving daily application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84 days).
- Trial name
- Phase2b (NCT03538951)
- Testing
- 10% VDA-1102, 20% VDA-1102
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Vidac Pharma
Actinic Keratosis
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.
- Trial name
- NCT02385318
- Testing
- Ingenol Mebutate (Perrigo), Ingenol Mebutate (Reference)
- Volunteers
- 519 people
- Sponsor
- Padagis LLC
Smoldering Multiple Myeloma
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56^dim cells (a marker for the health of the body's immune system)
- Trial name
- NCT01441973
- Testing
- Elotuzumab (BMS-901608; HuLuc63)
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bristol-Myers Squibb
Non-melanomatous Skin Cancer, Precancerous Condition
Photodynamic Therapy in Treating Patients With Skin Cancer
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer.
- Trial name
- NCT00002975
- Testing
- aminolevulinic acid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Roswell Park Cancer Institute
Uterine Cervical Dysplasia, Uterine Cervix Cancer
The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams
This study is intended to improve the patient experience of communication of colposcopy results and follow-up recommendations to patients.
- Trial name
- NCT03296566
- Testing
- Patient Liaison
- Where
- Canada
- Volunteers
- 297 people
- Sponsor
- University of British Columbia
Cervical Cancer, Precancerous Condition
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
RATIONALE: Vaccines made from protein and DNA may help the body build an effective immune response to kill abnormal cells in the cervix. The use of vaccine therapy may prevent cervical cancer.
- Trial name
- NCT00121173
- Testing
- pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Intraepithelial Neoplasia, Uterine Neoplasms
A Trial for Patients With Advanced/Recurrent Cervical Cancer
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
- Trial name
- NCT00190983
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Precancerous/Nonmalignant Condition, Prostate Cancer
S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of selenium may be an effective way to prevent prostate cancer in patients who have neoplasia of the prostate.
- Trial name
- NCT00030901
- Testing
- L-selenomethionine
- Volunteers
- 619 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma, Precancerous/Nonmalignant Condition
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1.
- Trial name
- NCT00854581
- Testing
- PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Actinic Keratosis, Photodynamic Therapy
Photodynamic Therapy-Induced Immune Modulation: Part III
This study is designed as a double-blinded proof of concept of feasibility study to define if the immunosuppression associated with photodynamic therapy (PDT) can be blocked by treatment with cyclo-oxygenase-2 (COX-2) inhibitor…
- Trial name
- NCT03643744
- Testing
- Celecoxib 200mg
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Wright State University
Early Stage Esophageal Adenocarcinoma, Barrett Esophagus
Endoscopic Therapy of Early Cancer in Barretts Esophagus
This study is being done to see if treatment for esophageal cancer can be done using endoscopy for patients ineligible for surgical or radiological therapy.
- Trial name
- NCT00217087
- Testing
- Endoscopic Mucosal Resection, Photodynamic Therapy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
ACTINIC KERATOSIS
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.015% to Picato gel, 0.015% by establishing the therapeutic comparability of the two active products and the…
- Trial name
- NCT03200912
- Testing
- Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
- Where
- 23 sites in United States
- Volunteers
- 507 people
- Sponsor
- Actavis Inc.
Actinic Keratosis
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
- Trial name
- NCT02632110
- Testing
- ALA, Topical Solution Vehicle, IBL 10 mW
- Where
- 8 sites in United States
- Volunteers
- 137 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Leukoplakia, Erythroplakia
Treatment of Oral Premalignant Lesions With 5-ALA PDT
Oral leukoplakia within the mouth is a visible white patch which can develop into cancer if not treated. There is no good treatment for these lesions, apart from surgery which is associated with significant side effects and…
- Trial name
- NCT00571974
- Testing
- PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Arkansas
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment.
- Trial name
- NCT02547233
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 437 people
- Sponsor
- LEO Pharma
Precancerous/Nonmalignant Condition
Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed.
- Trial name
- NCT00524485
- Testing
- aminolevulinic acid, laser therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute